

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>SIGMA HEALTHCARE LIMITED ('Sigma')</b>
<b>ABN</b>	<b>15 088 417 403</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	<b>Vikesh RAMSUNDER</b>
<b>Date of last notice</b>	20 December 2023

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (j) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b>  Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
<b>Date of change</b>	9 July 2024, 12 February 2025, 13 February 2025 and 14 February 2025
<b>No. of securities held prior to change</b>	11,662,028 fully paid ordinary shares (which includes 10,179,605 shares under Sigma's Loan Funded Share Plan) 1,482,422 Sign-On Rights 240,462 2022/2023 STI Rights 3,112,283 EEG Rights
<b>Class</b>	Rights to acquire fully paid ordinary shares in Sigma  Fully paid ordinary shares in Sigma
<b>Number acquired</b>	1,253,717 rights 3,132,984 fully paid ordinary shares

+ See chapter 19 for defined terms.

## Appendix 3Y Change of Director's Interest Notice

<b>Number disposed</b>	11,662,028 ordinary shares
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	<p>Acquired rights – the rights were granted under Sigma's 2023/2024 STI Deferral Rights Plan and 2024 LTI Plan. Rights are issued for nil consideration and represent part of the employee incentive scheme component for Mr Ramsunder.</p> <p>Acquired shares – shares issued on the exercise of existing rights. No consideration is payable by the holder to Sigma on the exercise of a right. The corresponding rights lapse upon issuance of the shares.</p> <p>Disposed shares – average price of \$2.92 per share</p>
<b>No. of securities held after change</b>	3,132,984 fully paid ordinary shares 1,010,723 2024 LTI Rights
<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	<p>Issuance of rights under Sigma's 2023/2024 STI Deferral Rights Plan (242,994 rights) and 2024 LTI Plan (1,010,723 rights) on 9 July 2024.</p> <p>Conversion of 1,167,106 EEG Rights to ordinary shares and lapse of remaining 1,945,177 EEG Rights (replaced by a cash bonus of equivalent value) on 12 February 2025 in accordance with treatment under merger with Chemist Warehouse (see section 6.5.3.2 of Sigma's prospectus dated 10 February 2025)</p> <p>On-market disposal of shares on 13 February 2025 (1,482,423 ordinary shares and 10,179,605 LFSP shares)</p> <p>Exercise of rights and corresponding issuance of shares on 14 February 2025 (1,482,422 sign-on rights, 240,462 2022/2023 STI Rights and 242,994 2023/2024 STI Rights)</p>

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
---------------------------	-----

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
<b>Interest after change</b>	

**Part 3 – +Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	Yes, however see Sigma's ASX announcement of a Special Dispensation Period dated 12 February 2025 <a href="https://investorcentre.sigmahealthcare.com.au/static-files/db7ea038-9c8e-4fc0-aa9a-e4c51ec72f95">https://investorcentre.sigmahealthcare.com.au/static-files/db7ea038-9c8e-4fc0-aa9a-e4c51ec72f95</a>
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	
<b>If prior written clearance was provided, on what date was this provided?</b>	

---

+ See chapter 19 for defined terms.